Silence Therapeutics Hits $10M Milestone, Files 6-K

TL;DR

**Silence Therapeutics just hit a $10M milestone, signaling good news for their pipeline!**

AI Summary

Silence Therapeutics plc filed a 6-K report on February 23, 2024, announcing it achieved a $10 million milestone. This report, under Commission File Number 001-39487, includes a press release dated February 23, 2024, as Exhibit 99.1. The company, headquartered at 72 Hammersmith Road, London, operates in the pharmaceutical preparations industry.

Why It Matters

This milestone payment indicates progress in Silence Therapeutics' pipeline or partnerships, potentially boosting investor confidence and future revenue streams.

Risk Assessment

Risk Level: low — The filing reports a positive financial milestone, which generally reduces perceived risk for investors.

Key Numbers

• $10 million — Milestone Payment (Indicates a significant financial achievement for Silence Therapeutics plc)

Key Players & Entities

• Silence Therapeutics plc (company) — Registrant and filer of the 6-K report
• $10 million (dollar_amount) — Milestone achieved by Silence Therapeutics plc
• February 23, 2024 (date) — Date of the 6-K filing and the press release
• 001-39487 (company) — Commission File Number for Silence Therapeutics plc
• 72 Hammersmith Road, London W14 8TH, United Kingdom (company) — Address of Silence Therapeutics plc

FAQ

Key Financial Figures

• $10 Million — 23, 2024, Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Coll

Filing Documents

• d780300d6k.htm (6-K) — 9KB
• d780300dex991.htm (EX-99.1) — 9KB
• g780300g0223045427361.jpg (GRAPHIC) — 3KB
• 0001193125-24-043611.txt ( ) — 24KB

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Silence Therapeutics plc, dated February 23, 2024. EXHIBIT INDEX Exhibit No. Description 99.1 Press release, dated February 23, 2024, Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Silence Therapeutics plc By: /s/ Craig Tooman Name: Craig Tooman Title: President and Chief Executive Officer Date: February 23, 2024

View Full Filing

View this 6-K filing on SEC EDGAR